Search results
FDA clears first digital treatment for depression, but experts caution that research is still early
CNN via Yahoo News· 1 month agoThe US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital...
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Benzinga via Yahoo Finance· 12 months agoOtsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H. Lundbeck A/S have received...
Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug
Reuters via Yahoo News· 12 months agoPatients with Alzheimer's sometimes show signs of extreme aggression or become restless and anxious...
Lundbeck, Otsuka announce positive phase III results for Alzheimer's agitation drug
Reuters via Yahoo News· 2 years agoCOPENHAGEN (Reuters) - Danish drugmaker Lundbeck and Japan's Otsuka Pharmaceutical on Monday announced positive Phase III results for its brexpiprazole drug used to treat agitation in patients ...
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
Zacks via Yahoo Finance· 4 months agoPer the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug....
Smartphone app approved as treatment for depression. 5 things to know about Rejoyn
Miami Herald via Yahoo News· 1 month agoThe U.S. Food and Drug Administration (FDA) is allowing the use of mobile app Rejoyn to be the first...
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
Investor's Business Daily· 3 weeks agoAnalysts applauded Vertex Pharmaceuticals on Thursday for its acquisition of Alpine Immune Sciences...
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?
Motley Fool· 12 months agoAXS-05 met its primary and secondary goals in the study, and importantly, looked to be on track to...
Aurinia Pharmaceuticals Inc (AUPH) Reports 60% Increase in Q3 Net Product Revenue
GuruFocus.com via Yahoo Finance· 6 months agoNet product revenue of $40.8 million for Q3 2023, a 60% increase over Q3 2022 Total net revenue of $130.4 million for the nine months ended September 30, 2023, a 24% increase over the same period ...
Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues
Zacks via Yahoo Finance· 9 months agoEsperion Therapeutics ESPR incurred a loss of 46 cents per share in the second quarter of 2023,...